InSphero AG Secures CHF 20 Million Series C Financing
Celebratory fireworks may be the July theme in the United States and France, but InSphero's securing of CHF 20 million in Series C financing from WILD Group Management LLC, is triggering pyrotechnic-worthy celebration in Schlieren, Switzerland as well. The recently finalized investment, announced in Wednesday's press release, is being used to rapidly expand InSphero's global footprint and broaden its portfolio of novel 3D microtissues and contract research services for 3D drug safety and efficacy testing.
InSphero CEO Dr. Jan Lichtenberg says, "this investment is an affirmation of InSphero's valuable, more predictive liver, islet and tumor model systems for use throughout the drug development process," and is a direct result of the growing adoption of InSphero's 3D models by major pharma companies since 2014.
Read the entire press release here, and thank you to all of our dedicated employees, loyal customers, strategic business partners, and key investors for helping us achieve the latest milestone in InSphero's rapidly evolving success story!